Double-blind assessment of the activity of minaprine (30038-CB) in child psychiatry.
A double-blind, crossover trial was carried out in 26 children with psychiatric disorders to assess the effectiveness of treatment with minaprine (100 mg per day) or placebo, each treatment being given in random order for 4 weeks. Patients were assessed before treatment and at 14 day intervals using a modified 34-item Hamilton rating scale. The results showed a definite therapeutic superiority of minaprine over placebo and a good response was achieved in over 50% of the children, including those showing signs of the "hyperactive syndrome'. Minaprine was well tolerated by all the patients.
D000293:Adolescent; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D009025:Morpholines / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use*
D000928:Antidepressive Agents; D009025:Morpholines; D011724:Pyridazines; C006149:minaprine